RxDoctor Payments Data

Andelka Losavio, MD

Gastroenterology · Winfield, ILNPI 1831315852

Payments from drug & device makers

$1,470in general payments, 2019–2025

Across 70 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$530
  • Bristol Myers Squibb$241
  • Aimmune Therapeutics, Inc.$125
  • Medtronic$112
  • Takeda Pharmaceuticals U.S.A., Inc.$111
  • Pfizer$95
  • plus $256 from 5 others

What the payments were for

  • Food & beverage$1,40596%
  • Education$644%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,470 in reported general payments places this provider in the 50th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$175,241
Medicare patients
512
Services billed
2,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab48$1,313,124
Humira(Cf) PenAdalimumab21$386,223
CreonLipase/Protease/Amylase70$163,680
XifaxanRifaximin24$63,862
ViberziEluxadoline17$22,291
MotegrityPrucalopride Succinate19$21,206
LinzessLinaclotide23$19,649
Mesalamine32$17,801
TrulancePlecanatide16$14,431
Balsalazide Disodium22$7,947
Mesalamine ErMesalamine19$5,302
Famotidine305$4,705
Budesonide DrBudesonide40$4,430
CholestyramineCholestyramine (With Sugar)54$4,051
Omeprazole334$3,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$58$1,313,12448 claims
AbbVieCreon, Viberzi, Linzess$530$205,620110 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$39$78,29340 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$111$21,20619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Winfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →